1. Home
  2. ORMP vs EARN Comparison

ORMP vs EARN Comparison

Compare ORMP & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc.

N/A

Current Price

$4.71

Market Cap

170.3M

Sector

Health Care

ML Signal

N/A

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

N/A

Current Price

$4.26

Market Cap

169.8M

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
ORMP
EARN
Founded
2002
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
170.3M
169.8M
IPO Year
2010
2012

Fundamental Metrics

Financial Performance
Metric
ORMP
EARN
Price
$4.71
$4.26
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
220.5K
348.0K
Earning Date
05-14-2026
06-16-2026
Dividend Yield
6.51%
20.51%
EPS Growth
412.50
N/A
EPS
2.76
N/A
Revenue
$2,000,000.00
N/A
Revenue This Year
N/A
$7.69
Revenue Next Year
N/A
$19.57
P/E Ratio
$1.69
N/A
Revenue Growth
49.25
N/A
52 Week Low
$2.09
$4.25
52 Week High
$5.47
$5.77

Technical Indicators

Market Signals
Indicator
ORMP
EARN
Relative Strength Index (RSI) 48.89 46.04
Support Level $3.91 $4.29
Resistance Level $5.10 $4.49
Average True Range (ATR) 0.24 0.06
MACD -0.06 -0.01
Stochastic Oscillator 8.43 23.81

Price Performance

Historical Comparison
ORMP
EARN

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.

Share on Social Networks: